Myriad Genetics and Lumea Inc. partner to integrate molecular diagnostics into Lumea's digital pathology platform, enhancing cancer care efficiency. Myriad Genetics and Lumea Inc. have announced a ...

Labroots is excited to announce our 14th Annual Precision Medicine: Genomics, Genetics & Molecular Diagnostics Virtual Event Series 2026 held on May 13th, 2026! The Precision Medicine: Genomics, ...

Renal tumor pathology has evolved considerably, expanding from two main types of renal malignant tumors to over 20 distinct types. Diagnostic criteria have advanced from purely morphological features ...

Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved ...

Labroots is excited to announce our 13th Annual Precision Medicine: Genomics, Genetics & Molecular Diagnostics Virtual Event Series 2025 held on May 14th, 2025! The Precision Medicine: Genomics, ...

The Southern blot, which detects specific DNA sequences, was one of the first molecular diagnostic methods to be widely adopted. 2 This type of probe-based assay uses a single-stranded oligonucleotide ...

The majority of rare diseases have a genetic cause. The underlying genetic alteration can be found more and more easily, for example by means of exome sequencing (ES), leading to a molecular genetic ...

The Achromatopsia Market is experiencing substantial growth, expected to increase from USD 121.99 million in 2026 to USD 191.22 million by 2032 at a compound annual growth rate of ...

Integration of AI with image-based genomics, consolidation towards integrated platforms, and growing focus on companion diagnostics bolster growthDublin, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The ...

Fulgent Genetics agrees to buy StrataDx and assets from Bako Diagnostics for $55.5 million. Learn how this cash deal expands ...